Varvis® Webinar on demand:
Liquid biopsy in breast cancer
using NGS
NGS-based liquid biopsy assays combine an ultralow detection limit with broad genomic coverage and therefore offer a comprehensive testing strategy. However, the complexity of the wetlab process and the data processing have previously been challenging obstacles. In our webinar we will point out a possible approach on how to establish liquid biopsy in breast cancer using NGS.
Established liquid biopsy assays like ddPCR allow to investigate specific low-level point mutations. However, broad genomic coverage is important to utilize liquid biopsy as a prognostic tool in breast cancer. NGS-based liquid biopsy assays can achieve both: an ultralow detection limit and broad genomic coverage. The complexity of the wetlab process and the data processing have previously been obstacles in clinical diagnostics. We provide an update on recent improvements in NGS library preparation as well as validated software solutions which enable state-of-the-art diagnostics for breast cancer patients.
Presented by:
Interested in more?
Learn more about
Clinical application of liquid biopsy in breast cancer
Dr. Simon von Ameln,
Onkologische Praxis am Marienhospital Aachen/ Metares e.V.
In the first part of our webinar, Dr. Simon von Ameln will give an overview of available therapies and current state-of-the-art breast cancer diagnostics and how he established liquid biopsy using NGS. Using real-life case examples, he will illustrate the utility of these highly-sensitive assays.
The new xgen™ Prism DNA Library Prep Kit
Peter Verhasselt, PhD,
Integrated DNA Technologies
What are the challenges in NGS when performing cancer research and what is new and special in the xGen™ Prism kit to address these challenges?
Validation of liquid biopsy: knowing your analytical performance
Dr. Ben Liesfeld,
Limbus Medical Technologies
Dr. Ben Liesfeld will demonstrate how you can use NGS for low-frequency variant detection and how these complex assays can be validated according to AMP guidelines.
Our speakers
Clinical application of liquid biopsy in breast cancer
Dr. Simon von Ameln, Onkologische Praxis am Marienhospital Aachen / Metares e.V.
Dr. Simon von Ameln is a biologist by training and specialized in human genetics. He completed his doctoral thesis at the University of Cologne, Institute of Genetics, in 2011 with a research focus on hereditary hearing loss. After a few years doing postdoctoral research, he decided to leave research and to move forward to clinical diagnostics in 2016. Serving as a clinical scientist at SYNLAB Munich and ZOTZ|KLIMAS in Dusseldorf, he gained experience in NGS-based panel and exome diagnostics. Since 2019 Dr. Simon von Ameln is working in Oncology at the Marienhospital in Aachen, where he has established liquid biopsy using NGS technologies in-house.
The new xgen Prism DNA Library Prep Kit
Peter Verhasselt, PhD, Field Application Manager NGS, EMEA, Integrated DNA Technologies
Peter Verhasselt, PhD, has built a very strong experience in DNA and RNA sequencing, which has been applied in a broad spectrum of applications ranging from whole genome sequencing, over sequencing based expression analysis to targeted resequencing of cancer patients to guide treatment options (and more). In his new role as Field Application Manager for NGS EMEA at IDT (started May 2018), he is supporting the IDT customers and sales organization with his deep knowledge of NGS and its applications in the IDT product portfolio.
Validation of liquid biopsy: knowing your analytical performance
Ben Liesfeld, PhD, Co-Founder and Managing Director, Limbus Medical Technologies
Dr. Ben Liesfeld is Co-Founder and Managing Director of Limbus Medical Technologies, a medical software company whose mission is to support and facilitate genetic diagnostics. A physicist by training, he co-invented computer guided laser surgery devices for ophthalmology. When accepting a position in a clinical laboratory in 2013 he learned about the huge potential and the challenges of diagnosing rare diseases using NGS. This led him to create an independent enterprise to leverage software and real-world evidence in order to solve the puzzles of genetic diseases.